A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Public ClinicalTrials.gov record NCT06465069. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Study identification
- NCT ID
- NCT06465069
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 420 participants
Conditions and interventions
Conditions
- Metastatic Solid Tumor
- Recurrent Solid Tumor
- Advanced Solid Tumor
- Urinary Bladder Neoplasm
- Triple Negative Breast Cancer
- Non-small Cell Lung Cancer
- Esophageal Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Cervical Cancer
- Head and Neck Squamous Cell Carcinoma
- Prostate Cancer
- Renal Pelvis Cancer
- Bladder Cancer
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2024
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2027
- Last update posted
- Aug 23, 2026
2024 – 2027
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010-0269 | Recruiting |
| University of California, San Diego (UCSD) - Moores Cancer Center | La Jolla | California | 92093 | Not yet recruiting |
| UCLA Department of Medicine-Hematology/Oncology | Los Angeles | California | 90024 | Recruiting |
| Sarah Cannon Research Institute at HealthOne | Denver | Colorado | 80218 | Recruiting |
| Florida Cancer Specialists and Research Institute | St. Petersburg | Florida | 33705 | Completed |
| University of Chicago Hospital | Chicago | Illinois | 60637 | Recruiting |
| IU Simon Cancer Center | Indianapolis | Indiana | 46202 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02215 | Recruiting |
| START Midwest Cancer and Hematology Centers of W Michigan | Grand Rapids | Michigan | 49546 | Recruiting |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63110 | Recruiting |
| NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute) | New York | New York | 10016 | Not yet recruiting |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029-6574 | Recruiting |
| Columbia University Irving Medical Center | New York | New York | 10032-3729 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | Recruiting |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Recruiting |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | Not yet recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4000 | Recruiting |
| South Texas Accelerated Research Therapeutics (START) | San Antonio | Texas | 78229 | Recruiting |
| University of Utah - Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | Recruiting |
| START Mountain Region | West Valley City | Utah | 84119 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06465069, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06465069 live on ClinicalTrials.gov.